5/15
08:00 am
atrc
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
Medium
Report
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
5/4
09:21 am
atrc
AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target [Yahoo! Finance]
Low
Report
AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target [Yahoo! Finance]
5/3
07:58 am
atrc
The past three years for AtriCure (NASDAQ:ATRC) investors has not been profitable [Yahoo! Finance]
Medium
Report
The past three years for AtriCure (NASDAQ:ATRC) investors has not been profitable [Yahoo! Finance]
5/3
07:45 am
atrc
AtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
AtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
5/2
03:58 pm
atrc
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $57.00 to $49.00. They now have a "buy" rating on the stock.
Low
Report
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $57.00 to $49.00. They now have a "buy" rating on the stock.
5/2
03:41 pm
atrc
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/2
12:14 pm
atrc
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at JPMorgan Chase & Co. from $42.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at JPMorgan Chase & Co. from $42.00 to $34.00. They now have an "overweight" rating on the stock.
5/2
08:11 am
atrc
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Needham & Company LLC from $46.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Needham & Company LLC from $46.00 to $40.00. They now have a "buy" rating on the stock.
5/1
09:35 pm
atrc
Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]
Medium
Report
Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]
5/1
07:39 pm
atrc
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
5/1
04:09 pm
atrc
AtriCure Reports First Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
AtriCure Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/1
04:01 pm
atrc
AtriCure Reports First Quarter 2024 Financial Results
High
Report
AtriCure Reports First Quarter 2024 Financial Results
4/30
08:00 am
atrc
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
Medium
Report
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
4/23
08:39 am
atrc
AtriCure upgraded at Oppenheimer on valuation [Seeking Alpha]
Low
Report
AtriCure upgraded at Oppenheimer on valuation [Seeking Alpha]
4/23
07:01 am
atrc
AtriCure, Inc. (NASDAQ: ATRC) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $32.00 price target on the stock.
Low
Report
AtriCure, Inc. (NASDAQ: ATRC) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $32.00 price target on the stock.
4/19
11:01 am
atrc
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management [Yahoo! Finance]
Low
Report
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management [Yahoo! Finance]
4/18
08:04 am
atrc
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management [Yahoo! Finance]
Low
Report
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management [Yahoo! Finance]
4/18
08:00 am
atrc
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
Low
Report
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
4/10
08:06 am
atrc
AtriCure, Inc. (NASDAQ: ATRC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.
Medium
Report
AtriCure, Inc. (NASDAQ: ATRC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.
4/10
08:00 am
atrc
AtriCure to Announce First Quarter 2024 Financial Results
Medium
Report
AtriCure to Announce First Quarter 2024 Financial Results
3/27
02:06 am
atrc
AtriCure, Inc. (NASDAQ: ATRC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
AtriCure, Inc. (NASDAQ: ATRC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/26
08:25 am
atrc
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
3/26
08:00 am
atrc
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
3/25
02:06 am
atrc
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer [Yahoo! Finance]
Low
Report
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer [Yahoo! Finance]
3/22
06:48 am
atrc
AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug [Yahoo! Finance]
Medium
Report
AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug [Yahoo! Finance]